Methods for assessing the ability of a candidate drug to suppress MHC class I expression

• US 5,556,754 A
• Filed: 06/07/1995
• Issued: 09/17/1996
• Est. Priority Date: 06/07/1993
• Status: Expired due to Term

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Inventors: Mozes, Edna, Napolitano, Giorgio, Kohn, Leonard, Saji, Motoyasu, Singer, Dinah S., Weissman, Jocelyn, Ledley, Fred D.
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): MYERS, CARLA J
• Application Number:
  US08/480,525
• Time in Patent Office: 468 Days
• Field of Search: 435/6, 435/91.1, 435/63, 435/94, 536/24.31, 536/24.33, 536/501, 935/77, 935/78, 935/34, 935/36, 935/8
• US Class Current: 435/6.16
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/145 having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) isothiourea A61K31/155
• CPC Class Codes: A61K 31/17 having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/5047 Cells of the immune system
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/56977 HLA or MHC typing

Abstract

The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.

Claims

1. A method for assessing the therapeutic potential of a candidate drug for treating autoimmune diseases by assessing the ability of said candidate drug to suppress MHC Class I molecules, said method comprising,

(a) treating mammalian cells with said drug;

(b) obtaining protein extracts from said cells in step (a) and combining said protein extracts with a MHC Class I regulatory nucleic acid sequence to allow formation of complexes between at least one protein from said extract and said MHC class I regulatory nucleic acid sequence;

(c) detecting said complexes;

wherein a decrease or increase in quantity of said complexes indicates said drug'"'"'s potential in treating autoimmune diseases, said autoimmune diseases being selected from the group consisting of rheumatoid arthritis, psoriasis, juvenile diabetes, primary idiopathic myxedema, systemic lupus erythematosus, autoimmune asthma, myasthenia gravis, scleroderma, chronic hepatitis, Addison'"'"'s disease, hypogonadism, pernicious anemia, vitiligo, alopecia areata, Coeliac disease, autoimmune enteropathy syndrome, idiopathic thrombocytic purpura, acquired splenic atrophy, idiopathic diabetes insipidus, infertility due to antispermatazoan antibodies, sudden hearing loss, sensoneural hearing loss, Sjogren'"'"'s Syndrome, polymyositis, autoimmune demyelinating diseases, multiple sclerosis, transverse myelitis, ataxic sclerosis, pemphigus, progressive systemic sclerosis, dermatomyositis, polyarteritis nodosa, chronic hepatitis, hemolytic anemia, progressive systemic sclerosis, glomerular nephritis and idiopathic facial paralysis.

2. A method for assessing the therapeutic potential of a candidate drug according to claim 1, wherein said autoimmune disease is systemic lupus erythematosus.

4. The method of claims 1, 2 or 3 further comprising the step of adding oligonucleotide K (SEQ ID NO:

38) to step (b), whereby the addition of oligo K prevents the ability of said candidate drug to decrease formation of said complexes.

8. The method of claims 1, 2 or 3, wherein said drug is selected from the group consisting of methimazole, methimazole derivatives, carbimazole, propylthiouracil, thionamides, thiourelylenes, thioureas and thioruea derivatives.

9. The method of claims 1, 2 or 3, wherein said nucleic acid sequence is selected from the group consisting of the PD1 promoter fragments designated 140 (bases 321 to 455 of SEQ ID NO:

1), 114 (bases 221 to 320 of SEQ ID NO;

1), 151 (bases 54 to 220 of SEQ ID NO;

1) and 238 (bases 456 to 692 of SEQ ID NO;

1).

10. The method of claims 1, 2 or 3, wherein said nucleic acid sequence consists of about a 200 base pair fragment from the 5'"'"' flanking region of the PD1 gene.

11. The method of claims 1, 2 or 3, wherein said nucleic acid sequences are the regulatory regions of the PD1 promoter.

12. The method of claims 1, 2 or 3, wherein said nucleic acid sequences are oligonucleotides containing the same sequence as the regulatory domains of the the 5'"'"' flanking region of the PD1 gene.

13. The method of claims 1, 2 or 3, wherein said nucleic acid sequence is a double stranded oligonucleotide selected from the group consisting of the S1 oligonucleotide (SEQ ID NO:

3) and its complementary sequence, the S2 (SEQ ID NO;

4) oligonucleotide and its complementary sequence, the S3 (SEQ ID NO;

10) oligonucleotide and its complementary sequence, the S5 oligonucleotide (SEQ ID NO;

5) and its complementary sequence, the S6 oligonucleotide (SEQ ID NO6) and its complementary sequence the S7 oligonucleotide (SEQ ID NO;

7) and its complementary sequence and the S8 oligonucleotide (SEQ ID NO;

8) and its complementary sequence.

14. The method of claims 1, 2 or 3, wherein said protein extracts are from mammalian FRTL-5 cells, thyrocytes, hepatocytes, neural tissue, muscle, fibroblasts, adipocytes, or HELA cells.

3. A method for assessing the therapeutic potential of a candidate drug for treating transplantation rejection by assessing the ability of said candidate drug to suppress MHC Class I molecules, said method comprising,

(a) treating mammalian cells with said drug;

(b) obtaining protein extracts from said cells in step (a) and combining said protein extracts with a MHC Class I regulatory nucleic acid sequence to allow formation of complexes between at least one protein from said extract and said MHC Class I regulatory nucleic sequence;

(c) detecting said complexes;

wherein a decrease or increase in the quantity of said complexes indicates said drug'"'"'s potential in treating transplantation rejection.

5. A method for assessing the therapeutic potential of a candidate drug for treating autoimmune diseases by assessing the ability of a candidate drug to suppress MHC Class I molecules, said method comprising:

(a) introducing a reporter gene operably linked to a MHC Class I regulatory sequence into a population of mammalian cells;

(b) treating said cells with said drug; and

(c) measuring activity of said reporter gene operably linked to said MHC Class I regulatory sequence, whereby decreased activity indicates said drug'"'"'s potential in treating autoimmune diseases, said autoimmune diseases being selected from the group consisting of rheumatoid arthritis, psoriasis, juvenile diabetes, primary idiopathic myxedema, systemic lupus erythematosus, autoimmune asthma, myasthenia gravis, scleroderma, chronic hepatitis, Addison'"'"'s disease, hypogonadism, pernicious anemia, vitiligo, alopecia areata, Coeliac disease, autoimmune enteropathy syndrome, idiopathic thrombocytic purpura, acquired splenic atrophy, idiopathic diabetes insipidus, infertility due to antispermatazoan antibodies, sudden hearing loss, sensoneural hearing loss, Sjogren'"'"'s Syndrome, polymyositis, autoimmune demyelinating diseases, multiple sclerosis, transverse myelitis, ataxic sclerosis, pemphigus, progressive systemic sclerosis, dermatomyositis, polyarteritis nodosa, chronic hepatitis, hemolytic anemia, progressive systemic sclerosis, glomerular nephritis and idiopathic facial paralysis.

7. A method for assessing the therapeutic potential of a candidate drug according to claim 5, wherein said autoimmune disease is systemic lupus erythematosus.

15. The method of claims 5, 6 or 7 wherein said reporter gene operably linked to said MHC Class I regulatory sequence is introduced into said mammalian cells by means selected from the group consisting of electroporation, transduction, transfection and lipofection.

16. The method of claims 5, 6 or 7 wherein said cells are selected from the group consisting of mammalian cell thyrocytes, hepatocytes, neural tissue, muscle, fibroblasts, adipocytes, and HELA cells.

17. The method of claims 5, 6 or 7, wherein said reporter gene is selected from the group consisting of chloramphenicol acetyltransferase (CAT) gene, the β

-galactosidase gene, the luciferase gene and human growth hormone (hGH).

6. A method for assessing the therapeutic potential of a candidate drug for treating transplantation rejection by assessing the ability of a candidate drug to suppress MHC Class I molecules, said method comprising:

(a) introducing a reporter gene operably linked to a MHC Class I regulatory sequence into a population of mammalian cells;

(b) treating said cells with said drug; and

(c) measuring activity of said reporter gene operably linked to said MHC Class I regulatory sequence, whereby decreased activity indicates said drug'"'"'s potential in treating transplantation rejection.